• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    British Journal Of Pharmacology

    British Journal Of Pharmacology

    JournalISSN 0007-1188eISSN 1476-5381中科院 医学 2区

    年发文量

    研究主题

    论文(73584)

    排序
    1NewDiffering Roles of the Calcitonin Gene‐related Peptide (CGRP) and Amylin Receptors in Migraine‐related Light Aversion and Gastrointestinal Dysfunction in Mice
    Jayme S. Waite,Adisa Kuburas, Quinn K. Hanigan, Jamie L. Thoma,Brandon J. Rea,Harold C. Flinn,Mhairi Nimick,Zoe Tasma,Debbie L. Hay,Levi P. Sowers,Andrew F. Russo

    Background and Purpose The neuropeptide calcitonin gene‐related peptide (CGRP) is a well‐established player in migraine. Current CGRP migraine therapeutics were designed to inhibit the canonical CGRP receptor, yet, based on in vitro studies, they can also inhibit to a lesser degree the amylin receptor 1 (AMY 1 ), which CGRP can also activate. This study explores the potential in vivo contributions of these receptors to migraine‐like symptoms in mice. Experimental Approach Receptor contributions were probed using light aversion as a surrogate for photophobia and diarrhoea as a readout for gastrointestinal dysfunction in outbred CD1 mice. Induction of diarrhoea was also measured in C57BL/6 J mice. CGRP and amylin were used as agonists, with two selective antagonists, olcegepant for the canonical CGRP receptor and AC187 for calcitonin receptor (CT)‐based receptors, including AMY 1 . Key Results CGRP and amylin induced light aversion in CD1 mice and diarrhoea in both strains. CGRP‐induced light aversion was partially rescued by AC187, but not olcegepant. Light aversion was fully rescued only by a combination of AC187 and olcegepant. In contrast, olcegepant fully blocked CGRP‐induced diarrhoea, while AC187 only partially blocked at high doses. As a control, olcegepant fully rescued CGRP‐induced periorbital touch hypersensitivity in CD1 mice. Conclusions and Implications More than one receptor contributes to CGRP‐induced light aversion, with a CT‐based receptor unexpectedly playing a major role. In contrast, the canonical CGRP receptor plays a major role in CGRP‐induced diarrhoea. Thus, targeting a CT‐based receptor may reduce photophobia with less adverse gastrointestinal effects in migraine patients.

    2026
    引用
    AI阅读
    加入学术空间
    2NewResponse to a Letter to the Editor Entitled ‘long‐acting Relaxin for Pulmonary Hypertension: from Systemic Pharmacodynamics to Disease‐site Pharmacology’
    John Diener, Hitesh Soni, Jason Booe, Jaime Darce, Peter McNamara, Marcella Ruddy, Anthony J. Muslin
    2026
    引用
    AI阅读
    加入学术空间
    3NewNew Anti‐inflammatory and Remodelling Drugs for Unmet Clinical Needs in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
    Ian M. Adcock

    There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β 2 ‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids in the same inhalation device for improved asthma control. The most recent step‐change is the introduction of targeted monoclonal antibodies in patients with severe asthma and frequent exacerbations with biomarkers reflecting high levels of Type 2 (T2) inflammation. In chronic obstructive pulmonary disease (COPD), advances in bronchodilator therapy have been made, but limited advances in treating the inflammation and lung remodelling changes are present. We need new therapeutic agents for patients with a sub‐optimal response to current drugs. The aim of this narrative review is to provide a summary of the potential future anti‐inflammatory approaches undergoing testing for asthma and COPD rather than provide a systematic review. These approaches aim to optimize current treatment regimens and to develop novel agents against differing aspects of asthma and COPD pathophysiology. However, clinical trial results highlight our limited understanding of the biology of asthma and COPD subtypes. Furthermore, failed studies provide insight into disease pathophysiology and may indicate responder/non‐responder populations. Various aspects of cytokine‐ and environment‐activated intracellular pathways are being targeted. These include receptor agonists and antagonists and inhibitors of the Janus kinase (JAK) and Bruton tyrosine kinase (BTK) pathways for use against both stable disease and for reducing disease exacerbations or ‘attacks’. New or better use of current biomarkers will provide non‐invasive means of patients most likely to respond to any one specific or combination of drugs.

    2026
    引用
    AI阅读
    加入学术空间
    4NewMitochondrial DNA‐cGAS‐STING Induces Macrophage Pyroptosis Via Phospho‐irf3‐mediated NLRP3 Expression in Ionising Radiation‐induced Atherosclerosis Progression
    Sainan Pang,Yuwu Chen,Xinxin Zhu, Xin Guan, Shaohua Ding, Deyang Yu,Tian Luan, Muping Liu,Manru Shi, Shan Jiang,Yang Cao,Jiayin Liu,

    Abstract Background and Purpose Ionising radiation (IR) is a major cancer‐treatment modality, yet the mechanisms driving IR‐triggered cardiovascular injury are poorly defined. This work aimed to uncover how IR accelerates atherosclerosis (AS) and the underlying molecular mechanisms. Experimental Approach We applied 9.4 T magnetic resonance imaging to evaluate atherosclerotic lesions. Single‐cell RNA sequencing was performed on carotid arteries. Apolipoprotein E (ApoE) knockout mice with caspase‐1 deletion and macrophage‐specific cGAS knockdown were used for in vivo validation. JASPAR prediction and dual‐luciferase reporter assays were implemented to verify transcriptional regulation of NLRP3. Key Results IR substantially aggravated atherosclerotic progression, accompanied by elevated pyroptosis‐related gene expression in macrophages within atherosclerotic plaques. Mechanistically, IR promoted cytoplasmic mtDNA release to activate the cGAS/STING/TBK1 axis and cause p‐IRF3 nuclear translocation. Phosphorylated IRF3 bound to the NLRP3 promoter and enhanced its transcription. Genetic ablation of caspase‐1 or macrophage‐specific cGAS knockdown alleviated IR‐driven AS progression. Conclusions and Implications Macrophage pyroptosis drives IR‐accelerated AS progression through the mtDNA/cGAS/STING/p‐IRF3 axis‐dependent transcriptional up‐regulation of NLRP3. Targeting the cGAS‐STING pathway may provide a therapeutic strategy for IR‐associated atherosclerotic plaque progression.

    2026
    引用
    AI阅读
    加入学术空间
    5NewTriptonide Alleviates Sepsis-Associated Acute Lung Injury by Suppressing the STAT3/HIF-1α-mediated Aerobic Glycolysis in Macrophages.
    Jun-Jie Zhu, Zhuo-Yao Ou, Hao-Chen Ma, Qiang Huang, L. Pan, Hua-Ting Xie, Guo-Quan Pan,Sheng-Wei Jin
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 73584 篇论文

    高被引作者

    作者引用发文
    R.M. Featherstone349722
    K.Diane Courtney349721
    George L. Ellman349721
    Valentino Andres349721
    Steve Alexander23715239
    Amrita Ahluwalia1827850
    Yung-Chi Cheng1823133
    William H. Prusoff1806622
    Moncada, S.1701771
    Michael Emerson165228

    高产作者

    作者引用发文
    Steve Alexander23715239
    Stephen Hill4388196
    Christoph Thiemermann7021187
    T. Bennett4546185
    S M Gardiner4313184
    Jane Mitchell6328153
    Jr Vane5767150
    Peter Jenner3491149
    Lan McGrath6511142
    P.P.A. Humphrey2360134

    相关期刊

    Naunyn-Schmiedeberg's Archives of Pharmacology
    Pharmacology and Therapeutics
    Antioxidants and Redox Signaling
    Acta pharmacologica Sinica
    Redox biology
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
    Pharmacological Reviews
    Pharmacological Research
    Biomarker Research
    Toxicology and Applied Pharmacology